Trump signed the same govt order within the remaining weeks of his first time period, however a court docket order later blocked the rule from going into impact.
WASHINGTON — President Donald Trump on Monday signed a sweeping govt order setting a 30-day deadline for drugmakers to electively decrease the price of pharmaceuticals within the U.S. or face new limits down the highway over what the federal government can pay.
The order calls on the well being division, led by Robert F. Kennedy Jr., to dealer new worth tags for medicine over the subsequent month. If offers usually are not reached, Kennedy might be tasked with growing a brand new rule that ties the value the U.S. pays for drugs to decrease costs paid by different international locations.
“We will equalize,” Trump mentioned throughout a Monday morning press convention. “We’re all going to pay the identical. We will pay what Europe pays.”
It is unclear what — if any — influence the Republican president’s govt order may have on thousands and thousands of Individuals who’ve non-public medical health insurance. The federal authorities has essentially the most energy to form the value it pays for medicine lined by Medicare and Medicaid.
Trump’s promised new — however unsure — financial savings on drug costs, simply hours after the Republican-led Home launched its new plan to trim $880 billion from Medicaid.
Taxpayers spend tons of of billions of {dollars} on pharmaceuticals, injectables, transfusions and different drugs yearly by means of Medicare, which covers practically 70 million older Individuals. Medicaid, which supplies nearly-free well being care for nearly 80 million poor and disabled folks within the U.S. additionally spends tens of billions of {dollars} annually for medicine.
Prime US drugmakers say Trump’s order is dangerous for sufferers
The nation’s pharmaceutical foyer, which represents the highest U.S. drugmakers, instantly pushed again in opposition to Trump’s order, calling it a “dangerous deal” for American sufferers. Drugmakers have lengthy argued that any threats to their earnings might influence the analysis they do to develop new medicine.
“Importing international costs from socialist international locations can be a nasty deal for American sufferers and staff,” Stephen J. Ubl, the president and CEO of PhRMA, mentioned in a press release. “It will imply much less remedies and cures and would jeopardize the tons of of billions our member corporations are planning to spend money on America.”
Trump’s so-called “most favored nation” strategy to Medicare drug pricing has been controversial since he first tried to implement it throughout his first time period. He signed the same govt order within the remaining weeks of his presidency, which known as for the U.S. to solely pay a lower cost that different international locations pay for some medicine — similar to injectables or most cancers medicine given by means of infusions — administered in a health care provider’s workplace.
That slender govt order confronted hurdles, with a court docket order that blocked the rule from going into impact underneath President Joe Biden’s administration. The pharmaceutical business argued that Trump’s 2020 try would give international governments the “higher hand” in deciding the worth of medicines within the U.S.
Trump says different international locations are accountable
Trump repeatedly defended pharmaceutical corporations, as a substitute blaming different international locations for the excessive worth Individuals pay for medicine, throughout a wide-ranging speech on the White Home on Monday. The president was flanked by Kennedy, Facilities for Medicare and Medicaid Companies administrator Dr. Mehmet Oz, Meals and Drug Administration commissioner Dr. Marty Makary and Nationwide Institutes of Well being director Jay Bhattacharya.
He did, nonetheless, threaten the businesses with federal investigations into their practices and opening up the U.S. drug market to herald extra imported drugs from different international locations.
“The pharmaceutical corporations make most of their earnings from America,” Trump mentioned. “That’s not a very good factor.”
Trump performed up the announcement over the weekend, boasting in a single publish that his plan might save “TRILLIONS OF DOLLARS.”
However on Monday, the White Home supplied no specifics for the way a lot cash the administration anticipates it might save.
The well being division’s prime leaders might be assembly with drug firm executives over the subsequent 30 days to supply new costs on medicine which might be based mostly off what different international locations pay, Oz mentioned on Monday.
Individuals are unlikely to see rapid financial savings
Individuals are unlikely to see reduction on rising drug prices rapidly due to the order, mentioned Rachel Sachs, a well being legislation professional at Washington College.
“It actually does appear the plan is to ask producers to voluntarily decrease their costs to some level, which isn’t identified,” Sachs mentioned. “If they don’t decrease their costs to the specified level, HHS shall take different actions with a really lengthy timeline, a few of which might probably, years sooner or later, decrease drug costs.”
The well being division has essentially the most authority to alter the costs of medicine lined by Medicare and Medicaid as a result of it will probably set laws. Even nonetheless, the company’s energy to take action is proscribed. Congress simply permitted in 2022 a brand new legislation that enables Medicare to barter the value it pays for a handful of pharmaceuticals beginning in 2026. Earlier than the legislation, Medicare paid what the drug corporations charged. Drug corporations unsuccessfully sued over the implementation of the legislation.
The worth that thousands and thousands of Individuals lined by non-public insurance coverage pay for medicine is even tougher for the company to control.
The U.S. routinely outspends different nations on drug costs, in contrast with different massive and rich international locations, an issue that has lengthy drawn the ire of each main political events, however an enduring repair has by no means cleared Congress.
Trump got here into his first time period accusing pharmaceutical corporations of “getting away with homicide” and complaining that different international locations whose governments set drug costs had been making the most of Individuals.
Trump says he’ll ‘do the fitting factor’
Forward of the announcement, Trump overrated his rhetoric towards the business once more on social media, writing that the “Pharmaceutical/Drug Firms would say, for years, that it was Analysis and Improvement Prices, and that every one of those prices had been, and can be, for no motive in anyway, borne by the ‘suckers’ of America, ALONE.”
Referring to drug corporations’ highly effective lobbying efforts, he mentioned that marketing campaign contributions “can do wonders, however not with me, and never with the Republican Social gathering.”
“We’re going to do the fitting factor,” he wrote.
A number of pharmaceutical corporations gained floor within the inventory market on Monday morning. Merck, an organization that made $64.2 billion final 12 months with the assistance of its most cancers therapy Keytruda, jumped 3.9%. Pharma large Pfizer, which notched $63.6 billion in income in 2024, rose 2.5% whereas Gilead Sciences rose 5.8%.
Related Press writers Will Weissert in Washington and Damian Troise in New York contributed to this report.
Copyright 2025 Related Press. All rights reserved. This materials will not be revealed, broadcast, rewritten, or redistributed.
